Key Points
Oct 4 (Reuters) - Moderna (MRNA.O) on Wednesday said its combination vaccine to protect against both COVID-19 and influenza generated a strong immune response compared to individual shots for the viruses in an early-stage study...
Moderna said the combination generated antibodies similar to or greater than currently marketed flu vaccines, and was similar to its previous standalone COVID booster shot against the coronavirus...
The vaccine, called mRNA-1083, appeared to be effective against all four A and B strains of the flu in older adults when compared with widely used flu shots from GSK (GSK.L) and Sanofi (SASY.PA), according to the company...
Moderna also said the combination was found to be safe and tolerable, and that rates of adverse side effects were similar to those experienced by people who received its COVID-19 vaccine during the study...
In September, Moderna announced that its standalone flu vaccine had generated a stronger immune response against all four A and B strains of the influenza virus than available flu shots in a late-stage trial...
